Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
|ClinicalTrials.gov Identifier: NCT01487096|
Recruitment Status : Completed
First Posted : December 7, 2011
Last Update Posted : October 4, 2012
The primary objective of this study was to determine the safety and efficacy of teriflunomide in multiple sclerosis (MS) with relapses.
Secondary objectives were:
- To determine the effect of teriflunomide on additional magnetic resonance imaging (MRI) variables as well as clinical and quality of life measures.
- To investigate the pharmacokinetic and pharmacodynamic relationships.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Drug: Teriflunomide Drug: Placebo (placebo for teriflunomide)||Phase 2|
The total duration of the study period per participants was 46 weeks comprising 3 periods:
- a 4-week screening period,
- a 36-week double-blind treatment period,
- a 6-week post-treatment follow-up period.
Participants who successfully completed the double-blind treatment phase were offered the possibility to continue study treatment in the extension study LTS6048 - NCT00228163.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||179 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|
|Study Start Date :||April 2001|
|Primary Completion Date :||March 2003|
|Study Completion Date :||March 2003|
Placebo Comparator: Placebo
Placebo (for teriflunomide),
Drug: Placebo (placebo for teriflunomide)
Experimental: Teriflunomide 7 mg
Teriflunomide 7 mg:
Other Name: HMR1726
Experimental: Teriflunomide 14 mg
Teriflunomide 14 mg:
Other Name: HMR1726
- MRI assessment: number of unique active lesions per scan (T2/proton density and gadolinium-enhanced T1 scan analysis) [ Time Frame: 36 weeks ]
The number of unique active lesions per scan was calculated by dividing the sum of unique newly active lesions and unique persistently active lesions observed on treatment by the number of scans performed on treatment.
Unique newly active lesions were all unique T1 and T2 lesions identified, one or more times, in a scan but not in the previous scan and, that had not been classified as unique newly active in any previous scan.
Unique persistently active lesions were all unique T1 and T2 lesions identified, one or more times, in a scan and also in the previous scan.
- Overview of Adverse Events [AE] [ Time Frame: from first study drug intake up to 6 weeks after last intake or entry in the extension study, whichever came first ]AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
- MRI assessment: number of T1-enhancing lesions per scan [ Time Frame: 36 weeks ]
T1-enhancing lesions included:
- Newly enhancing T1 lesions: lesions enhanced on the current T1 scan but not enhanced in any previous T1 scan.
- Persistently enhancing T1 lesions: lesions enhanced on the current T1 scan and enhanced on the previous T1 scan.
- MRI assessment: number of T2-lesions per scan [ Time Frame: 36 weeks ]
- New T2-lesions: lesions that appeared on the current T2 scan but were not visible on any previous T2 scans.
- Newly enlarging T2-lesions: lesions that appeared enlarged on the current T2 scan but were stable on the previous T2 scan.
- Persistently enlarging T2-lesions: further enlarged lesions on the current T2 scan categorized as new or enlarging on the previous T2 scan.
- MRI assessment: Number of participants with no new lesions [ Time Frame: 36 weeks ]New lesions included new T2 lesions, new enhanced T1 lesions and unique newly active lesions.
- MRI assessment: Change from baseline in T2 burden of disease [ Time Frame: 36 weeks ]T2 burden of disease was defined as the total volume of all T2 lesions.
- Number of participants with progression on Expanded Disability Status Scale [EDSS] [ Time Frame: 36 weeks ]
EDSS is an ordinal scale in half-point increments that qualifies disability in patients with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation.
EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).
Progression was defined as an increase in EDSS score by at least 1-point when baseline EDSS score ≤5.5 or an increase in EDSS score by at least 0.5-point in when baseline EDSS score >5.5.
- Number of participants with MS relapse confirmed by Scripps Neurological Rating Scale [NRS] and EDSS scores. [ Time Frame: 36 weeks ]
A relapse was defined as the appearance, reappearance or worsening of a symptom attributable to MS. The change had to persist for at least 48 hours in the absence of fever and be preceded by stability or improvement for at least 30 days. Relapses were to be confirmed by Scripps NRS and EDSS scores.
NRS is a scale that qualifies the degree of impairment from a neurological exam of the following systems: mentation and mood, cranial nerves, motor nerves, deep tendon reflexes, sensory nerves, cerebellum, gait/trunk/balance, bladder/bowel/sexual dysfunction.
NRS score ranges from 0 to 100 (lower degree of impairment).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01487096
|Toronto, Ontario, Canada|
|Study Director:||Clinical Study Director||Clinical Science & Operation - sanofi-aventis|